stonks4u
Sign up free
TCRX logo

TCRX TScan Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$0.78
+0.01 (+0.88%)

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic …

Market Cap: $47.56Mwww.tscan.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 12Aug 12

Quote

Day Range
$0.75 – $0.78
52-Week Range
$0.72 – $2.57
Volume
$277.2K
Market Cap
$47.56M
50-Day Avg
$0.90
200-Day Avg
$1.05
Prev Close
$0.77
Open
$0.77

Valuation & Ratios

P/E Ratio
-1.00
EPS
$-1.00
P/B Ratio
1.05
P/S Ratio
12.58
Debt/Equity
0.76
Current Ratio
8.41
Dividend Yield
+0.0%
Gross Margin
+72.2%

Returns & Efficiency

Return on Equity
-105.4%
Return on Assets
-56.7%
FCF Yield
-107.6%
EV/EBITDA
-0.58

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$10.32M$-129.77M$-1.00
2024$2.82M$-127.50M$-1.14
2023$21.05M$-89.22M$-1.36
2022$13.54M$-66.22M$-2.74
2021$10.14M$-48.63M$-2.03

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.30 per share

6of 7 quarters beat consensus

Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.23 vs $-0.25beat
  • Wed, May 6$-0.22 vs $-0.22beat
  • Wed, Mar 4$-0.18 vs $-0.27beat
  • Wed, Nov 12$-0.28 vs $-0.35beat
  • Tue, Aug 12$-0.28 vs $-0.28beat
  • Tue, May 6$-0.26 vs $-0.28beat

Estimates and results for TCRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

TCRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·3d ago·Negative

    TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology

    View source ↗